FDA gives mitomycin gel green light for low-grade upper tract urothelial cancer
April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper tract urothelial cancer. The approval was based on the Phase III OLYMPUS...
View ArticleSig3 mutation and immune score determine responses to combination PARP and...
Immune checkpoint inhibitors have shown promising therapeutic outcomes in many types of cancer, but ovarian cancer has been an exception. Thus, developing new strategies to improve the efficacy of...
View ArticleClik here to view.
FDA approve tucatinib for advanced unresectable or metastatic HER2-positive...
Seattle Genetics have announced the U.S. Food and Drug Administration (FDA) have granted approval for tucatinib in combination with trastuzumab and capecitabine for adult patients with advanced...
View ArticleTP53 mutations predict sensitivity to adjuvant chemotherapy in pancreatic...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive gastrointestinal malignancy and is often associated with a poor prognosis. Surgery remains the only treatment modality for PDAC that is...
View ArticleADAURA: osimertinib demonstrates significant clinical benefit in adjuvant...
The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung cancer (NSCLC) were presented at the plenary session during...
View ArticleFirst-line therapy with TKIs in NSCLC
Advances in treatment options for anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) have improved patient outcomes considerably in the last few years. This article highlights some...
View ArticleHead and neck cancer updates presented at ESMO 2020
EPIC-OPC study: misclassification of OPC patients The presence of human papillomavirus p16 alone is not sufficient to classify oropharyngeal cancer (OPC) as HPV-positive,1 therefore, it is important...
View ArticleRxPONDER: sparing chemotherapy in post-menopausal patients with node-positive...
The de-escalation and treatment personalization of patients with early breast cancer has advanced in recent years, with studies such as TAILORx (NCT00310180) demonstrating adjuvant endocrine therapy...
View ArticleEffect of fecal microbiota transplantation on anti-PD-1 resistant metastatic...
Advanced melanoma is an aggressive skin cancer characterized by poor survival and poor response to systemic cytotoxic chemotherapy. The use of anti-PD-1 immune checkpoint blockade molecules such as...
View ArticleAccelerating the pace from bench to beside: the NIHR Oncology Translational...
In a nationwide effort to prioritize and accelerate translational research, a brand-new oncology research collaboration has been established by The National Institute for Health Research (NIHR),...
View ArticleDostarlimab subject to accelerated FDA approval for the treatment of advanced...
The Food and Drug Administration (FDA) granted accelerated approval to dostarlimab on April 2021 for patients with recurrent or advanced deficient mismatch repair (dMMR) endometrial cancer that have...
View ArticleFDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of mobocertinib for patients with metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor...
View ArticleFDA grants priority review for fixed-dose relatlimab plus nivolumab in...
The U.S Food and Drug Administration (FDA) has granted priority review for the fixed-dose combination of relatlimab, a LAG-3 targeting antibody, plus nivolumab based on the findings from...
View ArticlePHS290: a novel scoring algorithm provides a promising approach to screening...
A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple ancestries, providing the potential to improve...
View Article177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC
As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide Tetraxetan) as a radioligand therapy for previously-treated patients with...
View ArticleMOUNTAINEER: Tucatinib plus trastuzumab demonstrates good efficacy for the...
In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to approximately 52,580 deaths in 2022.[1] Human epidermal growth factor receptor 2...
View ArticleEV-103 Cohort K: Promising data for first-line combination therapy of...
EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with other therapies for patients with urothelial...
View ArticleNew research elucidates how air pollution causes lung cancer in never-smokers
Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air pollution promotes the development of lung cancer in people who...
View ArticleTROPiCS-02: Overall survival benefit of sacituzumab govitecan in HR+/HER2-...
Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy payload, enabling a targeted therapeutic response....
View ArticleFirst-line maintenance with olaparib monotherapy and in combination...
Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The prognosis of patients with advanced ovarian cancer is very poor, and...
View Article